0001213900-22-035127.txt : 20220728 0001213900-22-035127.hdr.sgml : 20220728 20220627142707 ACCESSION NUMBER: 0001213900-22-035127 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20220627 FILER: COMPANY DATA: COMPANY CONFORMED NAME: InMed Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001728328 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: SUITE 310, 815 W. HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 1B4 BUSINESS PHONE: (604) 669-7207 MAIL ADDRESS: STREET 1: SUITE 310, 815 W. HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 1B4 CORRESP 1 filename1.htm

June 27, 2022

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, D.C. 20549

Re:	InMed Pharmaceuticals Inc. Registration Statement on Form S-1, filed on June 21, 2022 As amended by Amendment No. 1 to the Registration Statement on Form S-1, filed on June 24, 2022 File No. 333-265731

Ladies and Gentlemen:

On behalf of InMed Pharmaceuticals Inc., a British Columbia corporation (the “Company”), the undersigned hereby respectfully submits its request for acceleration of effectiveness. Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, the undersigned hereby requests that the effective date of the above referenced Registration Statement on Form S-1, as amended (the “Registration Statement”), be accelerated so that the same will become effective at 4:00 p.m., Washington, D.C. time, on Wednesday, June 29, 2022, or as soon as practicable thereafter.

Please notify Brian P. Fenske of Norton Rose Fulbright US LLP, counsel to the Company, at (713) 651-5557 or at brian.fenske@nortonrosefulbright.com, as soon as the Registration Statement has been declared effective, or if you have any other questions or concerns regarding this matter.

	Very truly yours,

	InMed Pharmaceuticals Inc.

	By:	/s/ Eric A. Adams
	Name:	Eric A. Adams
	Title:	President and Chief Executive Officer

GRAPHIC 2 image_001.jpg GRAPHIC begin 644 image_001.jpg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end